Patents by Inventor Michael Derek Edge

Michael Derek Edge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Monoclonal antibody to CEA, conjugates comprising said antibody and their therapeutic use
    Patent number: 6903203
    Abstract: An anti-CEA monoclonal antibody, designated 806.077, of murine origin is useful for the diagnosis and therapy of cancer. The antibody complementarity determining regions have the following sequences: heavy chain CDR1 DBYMH CDR2 WIDPENGDTE YAPKFRG, CDR3 LIYAGYLAMD Y; and light chain CDR1 SASSSVTYMH, CDR2 STSNLAS, CDR3 QQRSTYPLT. The antibody optionally is humanized and can be in the form of a conjugate with either an enzyme, such as carboxypeptidase, or a co-stimulatory molecule such as the extracellular domain of human B7.1.
    Type: Grant
    Filed: July 23, 2001
    Date of Patent: June 7, 2005
    Assignee: AstraZeneca UK Ltd.
    Inventors: Clive Graham Copley, Michael Derek Edge, Stephen Charles Emery
  • Nucleic acids
    Patent number: 6893843
    Abstract: Polypeptides, in particular the polypeptide of formula I: Ala-Gln-Glu-Pro-Val-Lys-Gly-Pro-Val-Ser-Thr-Lys- Pro-Gly-Ser-Cys-Pro-Ile-Ile-Leu-Ile-Arg-Cys-Ala- Met-Leu-Asn-Pro-Pro-Asn-Arg-Cys-Leu-Lys-Asp-Thr- Asp-Cys-Pro-Gly-Ile-Lys-Lys-Cys-Cys-Glu-Gly-Ser- Cys-Gly-Met-Ala-Cys-Phe-Val-Pro-Gln and analogues thereof which possess inhibitory activity against human leukocyte elastase. The polypeptides may be obtained by expression using plasmidic expression systems in hosts such as E. Coli and yeast, the polypeptide of formula I being also obtainable from psoriatic plaques.
    Type: Grant
    Filed: April 13, 2001
    Date of Patent: May 17, 2005
    Inventors: Enno Christophers, Oliver Wiedow, Jens-Michael Schroder, Michael Derek Edge, David Pioli
  • Polypeptides and polypeptide analogues
    Publication number: 20020187535
    Abstract: Polypeptides, in particular the polypeptide of formula I: 1 Ala-Gln-Glu-Pro-Val-Lys-Gly-Pro-Val-Ser-Thr-Lys- Pro-Gly-Ser-Cys-Pro-Ile-Ile-Leu-Ile-Arg-Cys-Ala-Met-Leu- Asn-Pro-Pro-Asn-Arg-Cys-Leu-Lys-Asp-Thr-Asp-Cys-Pro-Gly- Ile-Lys-Lys-Cys-Cys-Glu-Gly-Ser-Cys-Gly-Met-Ala-Cys- Phe-Val-Pro-Gln
    Type: Application
    Filed: April 13, 2001
    Publication date: December 12, 2002
    Inventors: Enno Christophers, Oliver Wiedow, Jens-Michael Schroder, Michael Derek Edge, David Pioli
  • Monoclonal antibody to CEA, conjugates comprising said antibody, and their therapeutic use in an adept system
    Publication number: 20020142359
    Abstract: The invention relates to an anti-CEA monoclonal antibody (named “806.077 antibody”) of murine origin and useful for the diagnosis and therapy of cancer. The antibody complementarity determining regions (CDRs) have the following sequences: heavy chain; CDR1 DNYMH, CDR2 WIDPENGDTE YAPKFRG, CDR3 LIYAGYLAMD Y; and light chain CDR1 SASSSVTYMH, CDR2 STSNLAS, CDR3 QQRSTYPLT. Humanised antibodies are described. The antibody is preferably in the form of a conjugate with either an enzyme suitable for use in an ADEPT system, especially a carboxypeptidase, or with a co-stimulatory molecule such as the extracellular domain of human B7.1.
    Type: Application
    Filed: July 23, 2001
    Publication date: October 3, 2002
    Inventors: Clive Graham Copley, Michael Derek Edge, Stephen Charles Emery
  • Anti-CEA antibody designated 806.077, hybridoma and method of manufacture
    Patent number: 6277599
    Abstract: An anti-CEA monoclonal antibody, designated 806.077, of murine origin is useful for the diagnosis and therapy of cancer. The antibody complementarity determining regions have the following sequences: heavy chain CDR1 DNYMH, CDR2 WIDPENGDTE YAPKFRG, CDR3 LIYAGYLAMD Y; and light chain CDR1 SASSSVTYMH, CDR2 STSNLAS, CDR3 QQRSTYPLT. The antibody optionally is humanized and can be in the form of a conjugate with either an enzyme, such as carboxypeptidase, or a co-stimulatory molecule such as the extracellular domain of human B7.1.
    Type: Grant
    Filed: October 29, 1998
    Date of Patent: August 21, 2001
    Assignee: Zeneca Limited
    Inventors: Clive Graham Copley, Michael Derek Edge, Stephen Charles Emery